A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients "TARGET-D"

Recruiting

Phase 4 Results N/A

Summary of Purpose

This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical management of 25[OH] Vit D levels.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 2 June 2017.

3 Apr 2017 15 Dec 2016 1 Apr 2021 1 Apr 2021 1 May 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available

Contacts